These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33513181)

  • 1. Serum TSH level as predictor of Graves' disease recurrence following antithyroid drug withdrawal: A systematic review.
    Subekti I; Kartiko GJ; Suhardi ZF; Muhadi ; Wisnu W
    PLoS One; 2021; 16(1):e0245978. PubMed ID: 33513181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study.
    Glinoer D; de Nayer P; Bex M;
    Eur J Endocrinol; 2001 May; 144(5):475-83. PubMed ID: 11331213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prevalence of transient thyrotoxicosis after antithyroid drug therapy in patients with Graves' disease.
    Kubota S; Takata K; Arishima T; Ohye H; Nishihara E; Kudo T; Ito M; Fukata S; Amino N; Miyauchi A
    Thyroid; 2008 Jan; 18(1):63-6. PubMed ID: 18302519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
    Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk Factors for the Relapse of Graves' Disease Treated With Antithyroid Drugs: A Systematic Review and Meta-analysis.
    Shi H; Sheng R; Hu Y; Liu X; Jiang L; Wang Z; Cui D
    Clin Ther; 2020 Apr; 42(4):662-675.e4. PubMed ID: 32139177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are pituitary and thyroid function tests useful for the monitoring of antithyroid drug treatment and the post therapeutic control of Graves' disease?
    Jaffiol C; Baldet L; Castelnau P; Papachristou C; Lapinski H; Rouaud R
    Horm Res; 1987; 26(1-4):137-45. PubMed ID: 2439427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of the medical treatment of Graves' disease (GD)].
    Peixoto MC; Coeli CM; Vaisman M
    Arq Bras Endocrinol Metabol; 2005 Jun; 49(3):410-9. PubMed ID: 16543996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Second Antithyroid Drug Treatment Is Effective in Relapsed Graves' Disease Patients: A Median 11-Year Follow-Up Study.
    Kim YA; Cho SW; Choi HS; Moon S; Moon JH; Kim KW; Park DJ; Yi KH; Park YJ; Cho BY
    Thyroid; 2017 Apr; 27(4):491-496. PubMed ID: 28001121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in Thyroid Peroxidase and Thyroglobulin Antibodies Might Be Associated with Graves' Disease Relapse after Antithyroid Drug Therapy.
    Choi YM; Kwak MK; Hong SM; Hong EG
    Endocrinol Metab (Seoul); 2019 Sep; 34(3):268-274. PubMed ID: 31565879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease.
    Zimmermann-Belsing T; Nygaard B; Rasmussen AK; Feldt-Rasmussen U
    Eur J Endocrinol; 2002 Feb; 146(2):173-7. PubMed ID: 11834425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
    Maugendre D; Massart C
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal iodine supplementation during antithyroid drug therapy for Graves' disease is associated with lower recurrence rates than iodine restriction.
    Huang H; Shi Y; Liang B; Cai H; Cai Q; Lin R
    Clin Endocrinol (Oxf); 2018 Mar; 88(3):473-478. PubMed ID: 29288501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves' disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission.
    Konishi T; Okamoto Y; Ueda M; Fukuda Y; Harusato I; Tsukamoto Y; Hamada N
    Endocr J; 2011; 58(2):95-100. PubMed ID: 21206137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK; Yoo WS; Kim DW; Chung HK
    Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T4 but not T3 administration is associated with increased recurrence of Graves' disease after successful medical therapy.
    Mastorakos G; Doufas AG; Mantzos E; Mantzos J; Koutras DA
    J Endocrinol Invest; 2003 Oct; 26(10):979-84. PubMed ID: 14759070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of pregnancy on subsequent relapse from Graves' disease after a successful course of antithyroid drug therapy.
    Rotondi M; Cappelli C; Pirali B; Pirola I; Magri F; Fonte R; Castellano M; Rosei EA; Chiovato L
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3985-8. PubMed ID: 18664537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of the 2nd generation assay for anti-TSH receptor antibodies to differentiate relapse of Graves' thyrotoxicosis from development of painless thyroiditis after antithyroid drug treatment for Graves' disease.
    Izumi Y; Takeoka K; Amino N
    Endocr J; 2005 Aug; 52(4):493-7. PubMed ID: 16127219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of Graves' disease after antithyroid drug treatment in Taiwan.
    Wang PW; Liu RT; Tung SC; Chien WY; Lu YC; Chen CH; Kuo MC; Hsieh JR; Wang ST
    J Formos Med Assoc; 1998 Sep; 97(9):619-25. PubMed ID: 9795530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapse of Graves' disease after successful outcome of antithyroid drug therapy: results of a prospective randomized study on the use of levothyroxine.
    Hoermann R; Quadbeck B; Roggenbuck U; Szabolcs I; Pfeilschifter J; Meng W; Reschke K; Hackenberg K; Dettmann J; Prehn B; Hirche H; Mann K;
    Thyroid; 2002 Dec; 12(12):1119-28. PubMed ID: 12593726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.